Matrix metalloproteinase and tissue inhibitor of metalloproteinase in serum and synovial fluid of osteoarthritic dogs

Summary

To better understand the mechanisms responsible for the pathological processes of osteoarthritis (OA) and to potentially identify a profile of changes that could be predictive of early OA, matrix metalloproteinase-1 (MMP-1) and tissue inhibitor of matrix metalloproteinase-2 (TIMP-2) in the synovial fluid and serum of normal and osteoarthritic dogs were examined. The concentration of MMP-1 in the synovial fluid of osteoarthritic dogs (0.62 ± 0.16), as measured by densitometry, was significantly higher than that found in control dogs (0.42 ± 0.19) (P = 0.03). The concentration of MMP-1 in the serum of osteoarthritic dogs (0.74 ± 0.16) was significantly less than that found in control dogs (0.87 ± 0.08) (P = 0.05). The concentration of TIMP-2 in the synovial fluid of osteoarthritic dogs (46.2 ± 21.9 ng/ml) was significantly less than that of control dogs (122.0 ± 66.5 ng/ml) (P = 0.009). The concentration of TIMP-2 in the serum of osteoarthritic dogs (116.2 ± 43.1 ng/ml) was not significantly different than that of control dogs (95.1 ± 94.4 ng/ml) (P = 0.554). In addition, a phospho-tyrosine immunoprecipitation and mass spectrometry were used to isolate and identify interferonalpha in canine synovial fluid.

Keywords

Matrix metalloproteinase - synovial fluid - serum

^* Presented at the annual scientific meeting of the American College of Veterinary Surgeons, Denver, CO, USA, October 2004.

• References

• 1 Aranapakam V, Davis JM, Grosu GT. et al. Synthesis and structure – Active relationship of N-substituted 4-arysulfonylpiperidine-4-hydroxamic acids as novel, orally active matrix metallo-proteinase inhibitors for the treatment of osteoarthritis. J Med Chem 2003; 46: 2376-96.
• 2 Birkedal-Hansen H, Moore WG, Bodden MK. et al. Matrix metalloproteinases: A review. Crit Rev in Oral Biol and Med 1993; 4: 197-250.
• 3 Byron CR, Orth MW, Venta PJ. et al. Influence of glucosamine on matrix metalloproteinase expression and activity in lipopolysaccharide-stimulated equine chondrocytes. Am JVet Res 2003; 64: 666-71.
• 4 Catterall JB, Cawston TE. Assay of MMPs and MMP inhibitors: Bioassays and immunoassays applicable to cell culture medium, serum, and synovial fluid. MethodsMol Biol 2003; 225: 353-64.
• 5 Clark IM, Powell LK, Ramsey S. et al. The measurement of collagenase, tissue inhibitor of metalloproteinase (TIMP), and collagenase-TIMP complex in synovial fluids from patients with osteoarthritis and rheumatoid arthritis. Arthritis Rheum 1993; 36: 372-9.
• 6 Clegg PD, Coughlan AR, Carter SD. Equine TIMP-1 and TIMP-2: identification, activity and cellular sources. EqVetJ 1998; 30: 416-23.
• 7 Dean DD, Martel-Pelletier J, Pelletier JP. et al. Evidence for metalloproteinase inhibitor imbalance in human osteoarthritic cartilage. J Clin Invest 1989; 84: 678-85.
• 8 Docherty AJ, O'Connell J, Crabbe T. et al. The matrix metalloproteinases and their natural inhibitors: prospects for treating degenerative tissue diseases. Trends Biotechnol 1992; 10: 200-7.
• 9 Fox DB, Cook JL. Synovial fluid markers of osteoarthritis in dogs. J Am Vet Med Assoc 2001; 219: 756-61.
• 10 Gamero AM, Larner AC. Vanadate facilitates interferon alpha-mediated apoptosis that is dependent on the Jak/Stat pathway. J Biol Chem 2001; 276: 13547-53.
• 11 Goldring MB. The role of the chondrocyte in osteoarthritis. Arthritis Rheum 2000; 43: 1916-26.
• 12 Hedbom E, Hauselmann HJ. Molecular aspects of pathogenesis in osteoarthritis: the role of inflammation. Cell Mol Life Sci 2002; 59: 45-53.
• 13 Hegemann N, Kohn B, Brunnberg L. et al. Biomarkers of joint tissue metabolism in canine osteoarthritic and arthritic joint disorders. Osteoarthritis Cartilage 2002; 10: 714-21.
• 14 Hegemann N, Wondimu A, Ullrich K. et al. Synovial MMP-3 and TIMP-1 levels and their correlation with cytokine expression in canine rheumatoid arthritis. Vet Immunol Immunopathol 2003; 91: 199-204.
• 15 Johnston SA. Osteoarthritis; Joint anatomy, physiology, and pathobiology. Vet Clin N Am 1997; 27: 699-723.
• 16 Lee T, Sumpio BE. Cell signalling in vascular cells exposed to cyclic strain: The emerging role of protein phosphatases. Biotechnol Applied Biochem 2004; 39: 129-39.
• 17 Lohmander LS, Hoerrner LA, Lark MW. Metalloproteinases, tissue inhibitor, and proteoglycan fragments in knee synovial fluid in human osteoarthritis. Arthritis Rheum 1993; 36: 181-9.
• 18 MacNaul KL, Chartrain N, Lark M. et al. Discoordinate expression of stromelysin, collagenase, and tissue inhibitor of metalloproteinases-1 in rheumatoid human synovial fibroblasts. J Biol Chem 1990; 265: 17238-45.
• 19 Manicourt DH, Fujimoto N, Obata K. et al. Serum levels of collagenase, stromelysin-1, and TIMP-1. Arthritis Rheum 1994; 37: 1774-83.
• 20 Martel-Pelletier J. Pathophysiology of Osteoarthritis. Osteoarthritis Cartilage 1999; 7: 371-3.
• 21 Martel-Pelletier J, McCollum R, Fujimoto N. et al. Excess ofmetalloprotease over tissue inhibitor of metalloproteinase may contribute to cartilage degradation in osteoarthritis and rheumatoid arthritis. Lab Invest 1994; 70: 807-15.
• 22 Nagase H, Woessner JF. Matrix Metalloproteinases. J Biol Chem 1999; 274: 21491-4.
• 23 Pelletier JP, Martel-Pelletier J. The Novartis-ILAR Rheumatology Prize 2001 Osteoarthritis: from molecule to man. Arthritis Res 2002; 4: 13-9.
• 24 Ray A, Kuroki K, Cook JL. et al. Induction of matrix metalloprotein 1 gene expression is regulated by inflammation-responsive transcription factor SAF-1 in osteoarthritis. Arthritis Rheum 2003; 48: 134-45.
• 25 Romerio F, Riva A, Zella D. Interferon-alpha2b reduces phosphorylation and activity of MEK and ERK through a Ras/Raf-independent mechanism. Brit JCancer 2000; 83: 532-8.
• 26 Rorvik AM, Grondahl AM. Markers of osteoarthritis: A review of the literature. Vet Surg 1995; 24: 255-62.
• 27 Thyrell L, Hjortsberg L, Arulampalam V. et al. Interferon alpha-induced apoptosis in tumour cells is mediated through the phosphoinositide 3-kinase/mammalian target of rapamycin signalling pathway. J Biol Chem 2004; 279: 24152-62.
• 28 Todhunter RJ, Yeager AE, Freeman KP. et al. Keratin sulphate as amarker of articular cartilage catabolism and joint treatment in ponies. Am J Vet Res 1993; 54: 1007-6.
• 29 Torpey N, Maher SE, Bothwell AL. et al. Interferon alpha butnotinterleukin 12 activates STAT4 signalling in human vascular endothelial cells. J Biol Chem 2004; 279: 26789-96.
• 30 Vaalamo M, Leivo T, Saarialho-Kere U. Differential expression of tissue inhibitors ofmatrix metalloproteinases (TIMP-1, -2, -3, -4) in normal and aberrant wound healing. Hum Pathol 1999; 30: 795-802.
• 31 Volk SW, Kapatkin AS, Haskins ME. et al. Gelatinase activity in synovial fluid and synovium obtained from healthy and osteoarthritic joints of dogs. Am JVet Res 2003; 64: 1225-33.
• 32 Winyard PG. Inflammation protocols Key stages in the acute inflammatory response and their relevance as therapeutic targets. Methods Mol Biol 2003; 225: 3-5.